Medical treatment of classic and nonclassic congenital adrenal hyperplasia

Advances in Experimental Medicine and Biology

Volumn 707, Issue , 2011, Pages 41-45

  Speiser, Phyllis W ^a  

^a Northwell Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROGEN; AROMATASE INHIBITOR; CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; GROWTH HORMONE; HYDROCORTISONE; LONG ACTING DRUG; MINERALOCORTICOID; PREDNISOLONE; SODIUM CHLORIDE; STEROID 21 MONOOXYGENASE; TESTOLACTONE;

ADRENAL CORTEX INSUFFICIENCY; AGE; ANDROGEN RELEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; CHILD GROWTH; COMBINATION CHEMOTHERAPY; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID THERAPY; CORTICOTROPIN RELEASE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; ELIXIR; EVENING DOSAGE; GROWTH ACCELERATION; GROWTH RATE; HUMAN; HYPOALDOSTERONISM; INFANCY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MORNING DOSAGE; NEWBORN SCREENING; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PUBERTY; SALT WASTING; SHORT STATURE; STEROID 21 MONOOXYGENASE DEFICIENCY; SUSPENSION; TABLET; VIRILIZATION;

ADRENAL HYPERPLASIA, CONGENITAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS;

EID: 79960719576     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-8002-1_9     Document Type: Article

References (21)

1. Bonfig,W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P., "Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: Deceleration of growth velocity during puberty," J. Clin. Endocrinol. Metab. 92, 1635-1639 (2007). (Pubitemid 46997164)
2. Punthakee, Z., Legault, L., & Polychronakos, C., "Prednisolone in the treatment of adrenal insufficiency: A re-evaluation of relative potency," J. Pediatrics 143(3), 402-405 (2003). (Pubitemid 37188329)
3. Rivkees, S. A. & Crawford, J. D., "Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth," Pediatrics 106(4), 767-773 (2000).
4. Merke, D. P., Cho, D., Anton Calis, K., Keil, M. F., & Chrousos, G. P., "Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 86(1), 441-445 (2001). (Pubitemid 32109832)
5. German, A., et al., "Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy," J. Clin. Endocrinol. Metab. 93(12), 4707-4710 (2008).
6. Bonfig,W., et al., "Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidence based recommendation," J. Clin. Endocrinol. Metab. 94 3882-3888 (2009).
7. Speiser, P. W., et al., "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline," J. Clin. Endocrinol. Metab. 95, 4133-4160 (2010).
8. Charmandari, E., Hindmarsh, P. C., Johnston, A., & Brook, C. G., "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Alterations in cortisol pharmacokinetics at puberty," J. Clin. Endocrinol. Metab. 86(6), 2701-2708 (2001). (Pubitemid 32545726)
9. Nimkarn, S., Lin-Su, K., Berglind, N., Wilson, R. C., & New, M. I., "Aldosterone-torenin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 92(1), 137-142 (2007). (Pubitemid 46067521)
10. Muthusamy K., et al., "Adult height outcomes in patients with congenital adrenal hyperplasia: A systematic review and meta-analysis," J. Clin. Endocrinol. Metab. 95, 4161-4172 (2010).
11. Gomes, L. G., et al., "Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: Effect on 21-hydroxylase deficiency," J. Clin. Endocrinol. Metab. 94, 89-95 (2010).
12. Speiser, P. W., Agdere, L., Ueshiba, H., White, P. C., & New, M. I., "Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase," N. Engl. J. Med. 324(3), 145-149 (1991).
13. Weise, M., et al., "Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise," J. Clin. Endocrinol. Metab. 89(8), 3679-3684 (2004). (Pubitemid 39071454)
14. Manoli, I., Kanaka-Gantenbein, C., Voutetakis, A., Maniati-Christidi, M., & Dacou- Voutetakis, C., "Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: Factors influencing the outcome," Clin. Endocrinol (Oxf). 57(5), 669-676 (2002). (Pubitemid 35316986)
15. Rasat, R., Espiner, E. A., & Abbott, G. D., "Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens," N. Z. Med. J. 108(1005), 311-314 (1995).
16. Weintrob, N., Dickerman, Z., Sprecher, E., Galatzer, A., & Pertzelan, A., "Non-classical 21-hydroxylase deficiency in infancy and childhood: The effect of time of initiation of therapy on puberty and final height," Eur. J. Endocrinol. 136(2), 188-195 (1997). (Pubitemid 27096348)
17. Laue, L., et al., "A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 81(10), 3535-3539 (1996). (Pubitemid 26339911)
18. Merke, D. P., et al., "Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 85(3), 1114-1120 (2000). (Pubitemid 32269358)
19. Quintos, J. B., Vogiatzi, M. G., Harbison, M. D., & New, M. I., "Growth hormone therapy alone or in combination with gonadotropin- releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 86(4), 1511-1517 (2001). (Pubitemid 32374896)
20. Lin-Su, K., et al., "Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia," J. Clin. Endocrinol. Metab. 90(6), 3318-3325 (2005). (Pubitemid 41014292)
21. Dacou-Voutetakis, C. and Karidis, N., "Congenital adrenal hyperplasia complicated by central precocious puberty: Treatment with LHRH-agonist analogue," Ann. N. Y. Acad. Sci. 687, 250-254 (1993). (Pubitemid 23217944)